90. Retinitis pigmentosa Clinical trials / Disease details

Clinical trials : 147 / Drugs : 176 - (DrugBank : 43) / Drug target genes : 49 - Drug target pathways : 110

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02609165 (ClinicalTrials.gov)	May 2015	12/10/2015	Nerve Growth Factor Eye Drops Treatment in Patients With Retinitis Pigmentosa and Cystoid Macular Edema	Nerve Growth Factor Eye Drops as a Novel Treatment for Vision Loss in Patients With Retinitis Pigmentosa: From Preclinical to Clinical Phase II Trial	Retinitis Pigmentosa;Cystoid Macular Edema	Drug: rhNGF 180 µg/ml eye drops solution;Drug: vehicle eye drops	Ospedale San Raffaele	Dompé Farmaceutici S.p.A	Completed	18 Years	N/A	All	45	Phase 2	Italy
2	EUCTR2014-000385-22-IT (EUCTR)	07/10/2014	12/05/2014	Nerve Growth Factor eye drops as a novel treatment for patients with Retinitis Pigmentosa.	Nerve Growth Factor eye drops as a novel treatment for vision loss in patients with Retinitis Pigmentosa: from preclinical toclinical Phase II trial. - NEMO	Retinitis pigmentosa with cystoid macular edema MedDRA version: 17.0;Level: LLT;Classification code 10054467;Term: Macular edema;System Organ Class: 100000004853 MedDRA version: 17.0;Level: PT;Classification code 10038914;Term: Retinitis pigmentosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Eye Diseases [C11]	Product Name: recombinant human Nerve Growth Factor (rhNGF) INN or Proposed INN: not yet assigned Other descriptive name: RECOMBINANT HUMAN NERVE GROWTH FACTOR (RHNGF)	Ospedale San Raffaele di Milano	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes		Phase 2	Italy